原发灶手术对初诊IV期乳腺癌生存影响:ABCSG-28 POSYTIVE随机III期试验
该前瞻性随机III期试验将90例初治IV期乳腺癌患者随机分为原发灶手术+全身治疗组与单纯全身治疗组,中位随访37.5个月,因招募不佳提前终止。手术组中位生存34.6个月,非手术组54.8个月(HR 0.691,95%CI 0.358-1.333;P=0.267),未能证明原发灶手术带来总生存获益。
要点
- 初诊IV期乳腺癌原发灶手术未显示总生存获益。
- 手术组中位生存34.6个月,非手术组54.8个月,差异无统计学意义。
- 试验因招募不佳提前终止,结果需谨慎解读。
核心结论
- ABCSG-28 POSYTIVE试验未能证明初诊IV期乳腺癌患者接受原发灶手术可带来总生存获益。
研究设计与样本
- 前瞻性随机III期试验,2011至2015年在奥地利入组90例既往未治疗的IV期乳腺癌患者,随机分为原发灶手术+全身治疗组(A组)或单纯全身治疗组(B组),各45例。
- 主要研究终点为总生存期(OS),中位随访37.5个月,因招募不佳提前终止。
主要发现
- 手术组中位生存34.6个月,非手术组54.8个月(HR 0.691,95%CI 0.358-1.333;P=0.267)。
- 手术组至远处进展时间13.9个月,非手术组29.0个月(HR 0.598,95%CI 0.343-1.043;P=0.0668)。
- 手术组cT3乳腺癌比例更高(22.2% vs 6.7%),cN2分期比例更高(15.6% vs 4.4%)。
- 两组一线全身治疗类型分布均衡。
临床怎么用
- 对于初诊IV期乳腺癌患者,原发灶手术不应作为常规推荐以改善生存。
- 临床决策应基于全身治疗,手术可用于特定姑息目的,但需个体化评估。
局限性
- 试验因招募不佳提前终止,样本量仅90例,统计效能不足。
- 手术组基线cT3和cN2比例更高,可能影响生存比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conflicting evidence exists regarding the value of surgical resection of the primary in stage IV breast cancer patients. OBJECTIVE: The prospective randomized phase III ABCSG-28 POSYTIVE trial evaluated median survival comparing primary surgery followed by systemic therapy to primary systemic therapy in de novo stage IV breast cancer. METHODS: Between 2011 and 2015, 90 previously untreated stage IV breast cancer patients were randomly assigned to surgical resection of the primary tumor followed by systemic therapy (Arm A) or primary systemic therapy (Arm B) in Austria. Overall survival (OS) was defined as the primary study endpoint. RESULTS: The trial was stopped early due to poor recruitment. Ninety patients (45 arm A, 45 arm B) were included; median follow-up was 37.5 months. Patients in the surgery arm had more cT3 breast cancer (22.2% vs 6.7%) and more cN2 staging (15.6% vs 4.4%). Both groups were well balanced with respect to the type of first-line systemic treatment. Median survival in arm A was 34.6 months, versus 54.8 months in the nonsurgery arm [hazard ratio (HR) 0.691, 95% confidence interval (95% CI) 0.358-1.333; P = 0.267]; time to distant progression was 13.9 months in the surgery arm and 29.0 months in the nonsurgery arm (HR 0.598, 95% CI 0.343-1.043; P = 0.0668). CONCLUSION: The prospective phase III trial ABCSG-28 (POSYTIVE) could not demonstrate an OS benefit for surgical resection of the primary in breast cancer patients presenting with de novo stage IV disease.
引用
- Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg. 2019. PMID: 31082916. doi:10.1097/SLA.0000000000002771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。